Collaboration to Advance the Development of Breakthrough Cell and Gene Therapies

Israel/USA: Collaboration Agreement Collaboration to Advance the Development of Breakthrough Cell and Gene Therapies

16.11.2021Editor: Alexander Stark

Global biotech company Orgenesis announced a collaboration agreement with Tel Aviv Sourasky Medical Center to advance Point-of-Care development and commercialization of cell and gene and therapies.

Orgenesis and the Tel Aviv Sourasky Medical Center plan to conduct collaborative cell-based research projects.
(Source: Public Domain / Pixabay )

Germantown/USA — Orgenesis has entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.

Under the agreement, the parties plan to conduct collaborative cell-based research projects, initially focused on advancing the clinical development and validation of Orgenesis’ CD19 CAR-T therapies, including CAR-T derived exosome products, utilizing Orgenesis’ proprietary T-cell culturing and point-of-care processes and systems. The parties also plan to deploy Orgenesis Mobile Processing Units and Labs (“Ompuls”) onsite to support joint research and validation activities for advanced cell and gene therapies developed by both Orgenesis and the Tel Aviv Sourasky Medical Center. Ompuls are multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities designed to significantly reduce the costs of advanced therapy production and accelerate the clinical development process at the point of care.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:47811288)

Israel/USA: Collaboration Agreement Collaboration to Advance the Development of Breakthrough Cell and Gene Therapies

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes